# Epicardial Cardiac Fat-CT (EPIC-CT)

> **NCT07297589** · PHASE3 · RECRUITING · sponsor: **Instituto Mexicano del Seguro Social** · enrollment: 136 (estimated)

## Conditions studied

- STEMI - ST Elevation Myocardial Infarction
- Epicardial Fat

## Interventions

- **DRUG:** Dapagliflozin 10 MG Oral Tablet
- **DRUG:** Semaglutide (Rybelsus®)

## Key facts

- **NCT ID:** NCT07297589
- **Lead sponsor:** Instituto Mexicano del Seguro Social
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2027-01
- **Final completion:** 2027-03
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07297589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07297589, "Epicardial Cardiac Fat-CT (EPIC-CT)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07297589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*